RU2009120990A - Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции - Google Patents
Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции Download PDFInfo
- Publication number
- RU2009120990A RU2009120990A RU2009120990/15A RU2009120990A RU2009120990A RU 2009120990 A RU2009120990 A RU 2009120990A RU 2009120990/15 A RU2009120990/15 A RU 2009120990/15A RU 2009120990 A RU2009120990 A RU 2009120990A RU 2009120990 A RU2009120990 A RU 2009120990A
- Authority
- RU
- Russia
- Prior art keywords
- testosterone
- ht1a
- sexual dysfunction
- pharmaceutical composition
- composition
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims abstract 42
- 229960003604 testosterone Drugs 0.000 title claims abstract 21
- 239000003723 serotonin 1A agonist Substances 0.000 title claims abstract 12
- 201000001880 Sexual dysfunction Diseases 0.000 title claims abstract 8
- 231100000872 sexual dysfunction Toxicity 0.000 title claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 10
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims abstract 8
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims abstract 8
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims abstract 8
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims abstract 8
- 230000001568 sexual effect Effects 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 206010057671 Female sexual dysfunction Diseases 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
1. Применение тестостерона и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается, по существу, за один час и указанный тестостерон - за 3,5-5,5 ч до сексуальной активности. ! 2. Применение тестостерона, ингибитора ФДЭ5 и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается, по существу, за один час, указанный ингибитор за 1-2 ч и указанный тестостерон - за 3,5-5,5 ч до сексуальной активности. ! 3. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой женскую сексуальную дисфункцию. ! 4. Фармацевтическая композиция, включающая тестостерон и агонист 5-HT1A, где указанная композиция предназначена для высвобождения, по существу, всего указанного 5-HT1A за один час и указанного тестостерона - за 3,5-5,5 ч до сексуальной активности. ! 5. Фармацевтическая композиция, включающая тестостерон, ингибитор ФДЭ5 и агонист 5-HT1A, где указанная композиция предназначена для высвобождения, по существу, всего указанного 5-HT1A за один час, указанного ингибитора ФДЭ5 - за 1-2 ч и указанного тестостерона - за 3,5-5,5 ч до сексуальной активности. ! 6. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает тестостерон и, по меньшей мере, одну композицию, которая включает агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций. ! 7. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает тестостерон, по меньшей мере, одну фармацевтическую композицию, которая включает ингибитор ФДЭ5 и, по меньшей м�
Claims (8)
1. Применение тестостерона и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается, по существу, за один час и указанный тестостерон - за 3,5-5,5 ч до сексуальной активности.
2. Применение тестостерона, ингибитора ФДЭ5 и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается, по существу, за один час, указанный ингибитор за 1-2 ч и указанный тестостерон - за 3,5-5,5 ч до сексуальной активности.
3. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой женскую сексуальную дисфункцию.
4. Фармацевтическая композиция, включающая тестостерон и агонист 5-HT1A, где указанная композиция предназначена для высвобождения, по существу, всего указанного 5-HT1A за один час и указанного тестостерона - за 3,5-5,5 ч до сексуальной активности.
5. Фармацевтическая композиция, включающая тестостерон, ингибитор ФДЭ5 и агонист 5-HT1A, где указанная композиция предназначена для высвобождения, по существу, всего указанного 5-HT1A за один час, указанного ингибитора ФДЭ5 - за 1-2 ч и указанного тестостерона - за 3,5-5,5 ч до сексуальной активности.
6. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает тестостерон и, по меньшей мере, одну композицию, которая включает агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций.
7. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает тестостерон, по меньшей мере, одну фармацевтическую композицию, которая включает ингибитор ФДЭ5 и, по меньшей мере, одну композицию, которая включает агонист 5-НТ1А, где указанный набор также включает инструкции по введению указанных композиций.
8. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой мужскую сексуальную дисфункцию.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076976.7 | 2006-11-03 | ||
| EP06076976A EP1925307A1 (en) | 2006-11-03 | 2006-11-03 | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012125827A Division RU2646447C2 (ru) | 2006-11-03 | 2012-06-20 | ПРИМЕНЕНИЕ АНАЛОГА ТЕСТОСТЕРОНА И АГОНИСТА 5-НТ1а ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009120990A true RU2009120990A (ru) | 2010-12-10 |
| RU2463054C2 RU2463054C2 (ru) | 2012-10-10 |
Family
ID=37846101
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120990/15A RU2463054C2 (ru) | 2006-11-03 | 2007-11-02 | Применение тестостерона и агониста 5-нт1a для лечения сексуальной дисфункции |
| RU2009120992/15A RU2491073C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции |
| RU2009120988/15A RU2464027C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции |
| RU2012125827A RU2646447C2 (ru) | 2006-11-03 | 2012-06-20 | ПРИМЕНЕНИЕ АНАЛОГА ТЕСТОСТЕРОНА И АГОНИСТА 5-НТ1а ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120992/15A RU2491073C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции |
| RU2009120988/15A RU2464027C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции |
| RU2012125827A RU2646447C2 (ru) | 2006-11-03 | 2012-06-20 | ПРИМЕНЕНИЕ АНАЛОГА ТЕСТОСТЕРОНА И АГОНИСТА 5-НТ1а ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US8653051B2 (ru) |
| EP (5) | EP1925307A1 (ru) |
| JP (8) | JP2010509211A (ru) |
| KR (6) | KR101796887B1 (ru) |
| CN (6) | CN101573119A (ru) |
| AU (3) | AU2007314736B2 (ru) |
| BR (3) | BRPI0717963A2 (ru) |
| CA (3) | CA2668316C (ru) |
| CY (1) | CY1117191T1 (ru) |
| DK (1) | DK2086544T3 (ru) |
| ES (1) | ES2561946T3 (ru) |
| HR (1) | HRP20160108T1 (ru) |
| HU (1) | HUE026752T2 (ru) |
| IL (5) | IL198459A (ru) |
| ME (1) | ME02410B (ru) |
| MX (3) | MX2009004695A (ru) |
| NO (3) | NO20092145L (ru) |
| NZ (3) | NZ577392A (ru) |
| PH (2) | PH12014501440A1 (ru) |
| PL (1) | PL2086544T3 (ru) |
| PT (1) | PT2086544E (ru) |
| RS (1) | RS54541B1 (ru) |
| RU (4) | RU2463054C2 (ru) |
| SI (1) | SI2086544T1 (ru) |
| UA (4) | UA103592C2 (ru) |
| WO (3) | WO2008054215A2 (ru) |
| ZA (3) | ZA200903835B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1750766E (pt) | 2004-05-11 | 2013-09-30 | Emotional Brain Bv | Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2709597A2 (en) * | 2011-05-13 | 2014-03-26 | Emotional Brain B.V. | Drug delivery system |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| JP5828923B2 (ja) | 2014-01-30 | 2015-12-09 | 国立大学法人高知大学 | ニッケル粉の製造方法 |
| JP5936783B2 (ja) | 2014-02-21 | 2016-06-22 | 国立大学法人高知大学 | ニッケル粉の製造方法 |
| JP6406613B2 (ja) | 2014-04-15 | 2018-10-17 | 住友金属鉱山株式会社 | 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法 |
| CN103947533B (zh) * | 2014-05-15 | 2015-12-16 | 青岛理工大学 | 生长环境可控的磁化水工厂化豆芽菜生产系统 |
| RU2600845C2 (ru) | 2014-07-04 | 2016-10-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3251436A (en) * | 1965-03-16 | 1966-05-17 | Dayton Steel Foundry Co | Spot-type disk brake |
| US3976776A (en) * | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| NZ209876A (en) * | 1983-10-17 | 1988-03-30 | Duphar Int Res | Piperazines and pharmaceutical compositions |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US5015646A (en) * | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
| US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| CA1335106C (en) * | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
| US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| RU2152787C2 (ru) * | 1994-06-02 | 2000-07-20 | Дан Рига | Лекарство против стресса, против снижения уровня активности и против старения и способ его получения |
| EP0804239B1 (en) | 1994-06-02 | 1999-09-15 | Dan Riga | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
| WO1996026940A1 (en) | 1995-03-01 | 1996-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
| ES2110380T1 (es) | 1995-03-14 | 1998-02-16 | Vivus Inc | Metodo y equipo para impedir el mal funcionamiento de la ereccion. |
| US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| AU5671496A (en) | 1995-05-15 | 1996-11-29 | Beth Israel Hospital | Use of dihydrotestosterone compounds for treating male sexual dysfunction |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6251436B1 (en) * | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US6242198B1 (en) | 1996-07-25 | 2001-06-05 | Cambridge Neuroscience, Inc. | Methods of treatment of eye trauma and disorders |
| ES2257813T3 (es) * | 1997-06-23 | 2006-08-01 | Cellegy Pharmaceuticals, Inc | Terapia de microdosis de condiciones vasculares mediante donadores de no. |
| US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| EP1027057A4 (en) * | 1997-10-28 | 2003-01-02 | Vivus Inc | TREATMENT OF FEMALE SEXUAL DISORDERS |
| US6246436B1 (en) * | 1997-11-03 | 2001-06-12 | Agilent Technologies, Inc | Adjustable gain active pixel sensor |
| TW542719B (en) * | 1998-02-23 | 2003-07-21 | Pfizer Res & Dev | Method of treating impotence due to spinal cord injury |
| US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| UA67802C2 (ru) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ИНГИБИТОРА цГМФ ФДЭ-5 (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ |
| JP2002543128A (ja) | 1999-04-30 | 2002-12-17 | リリー アイコス リミテッド ライアビリティ カンパニー | 雌性覚醒障害の処置 |
| US6632419B2 (en) * | 1999-05-04 | 2003-10-14 | Aradigm Corporation | Increasing libido in humans via acute testosterone administration |
| US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
| US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
| WO2000078328A2 (de) | 1999-06-17 | 2000-12-28 | Armin Johannes Becker | VERWENDUNG VON WACHSTUMSHORMON (hGH) ZUR THERAPIE SEXUELLER FUNKTIONSSTÖRUNGEN |
| RU2180591C2 (ru) | 1999-12-24 | 2002-03-20 | Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ | Средство для лечения сексуальных дисфункций у мужчин |
| DE10016548A1 (de) * | 2000-04-03 | 2001-10-11 | Bayer Ag | Polyurethan-Dispersionen |
| US6313172B1 (en) | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US6242436B1 (en) * | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| DK1315502T3 (da) | 2000-08-30 | 2010-07-19 | Unimed Pharmaceuticals Llc | Fremgangsmåde til behandling af erektil dysfunktion og til forøgelse af mænds libido |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| AU2002223572B2 (en) | 2000-09-29 | 2005-09-08 | Abbvie B.V. | Ion-strength independent sustained release pharmaceutical formulation |
| US20060287335A1 (en) * | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
| CN1496254A (zh) * | 2000-12-15 | 2004-05-12 | ������ҩ������˾ | 男性性功能障碍的治疗 |
| US20020107230A1 (en) | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| JP2005504721A (ja) | 2001-03-06 | 2005-02-17 | セレジィ ファーマシューティカルス， インコーポレイテッド | 尿生殖障害の処置のための化合物および方法 |
| RS75303A (sr) | 2001-03-28 | 2006-12-15 | Pfizer Limited | Derivati n-fenilpropilciklopentil-supstituisanog glutaramida kao nep inhibitori za fsad |
| EP1260225A1 (en) * | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| US20030027804A1 (en) | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20030022875A1 (en) * | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| EP1653966A1 (en) * | 2003-07-16 | 2006-05-10 | Pfizer Limited | Treatment of sexual dysfunction |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| ATE319426T1 (de) * | 2003-11-11 | 2006-03-15 | Mattern Udo | Nasenformulierung mit kontrollierter freisetzung von sexualhormonen |
| WO2005094827A1 (en) * | 2004-03-30 | 2005-10-13 | Kestrel Pharmaceuticals Inc. | Methods for treating sexual dysfunction |
| AU2005235422B2 (en) | 2004-04-22 | 2011-08-11 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders II |
| PT1750766E (pt) * | 2004-05-11 | 2013-09-30 | Emotional Brain Bv | Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina |
| JP2008536851A (ja) * | 2005-04-13 | 2008-09-11 | ユニメド ファーマスーティカルズ インク | 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法 |
| WO2006127057A1 (en) | 2005-05-24 | 2006-11-30 | Lyle Corporate Drvelopment, Inc. | Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction |
| WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| WO2007054791A2 (en) | 2005-11-08 | 2007-05-18 | L'oréal | Androgen glucuronides as markers of androgenic activity |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP2215072B1 (en) | 2007-11-28 | 2015-09-02 | UCB Pharma GmbH | Polymorphic form of rotigotine |
-
2006
- 2006-11-03 EP EP06076976A patent/EP1925307A1/en not_active Ceased
-
2007
- 2007-02-11 ME MEP-2016-33A patent/ME02410B/me unknown
- 2007-02-11 UA UAA200905653A patent/UA103592C2/ru unknown
- 2007-02-11 UA UAA200905652A patent/UA100119C2/ru unknown
- 2007-02-11 UA UAA200905654A patent/UA101948C2/ru unknown
- 2007-11-02 RS RS20160069A patent/RS54541B1/sr unknown
- 2007-11-02 KR KR1020167028902A patent/KR101796887B1/ko not_active Expired - Fee Related
- 2007-11-02 CA CA2668316A patent/CA2668316C/en not_active Expired - Fee Related
- 2007-11-02 CN CNA2007800491317A patent/CN101573119A/zh active Pending
- 2007-11-02 NZ NZ577392A patent/NZ577392A/xx not_active IP Right Cessation
- 2007-11-02 CN CN201410844093.6A patent/CN104524580A/zh active Pending
- 2007-11-02 MX MX2009004695A patent/MX2009004695A/es not_active Application Discontinuation
- 2007-11-02 EP EP07834665A patent/EP2086548A2/en not_active Withdrawn
- 2007-11-02 BR BRPI0717963-4A2A patent/BRPI0717963A2/pt not_active IP Right Cessation
- 2007-11-02 ES ES07834663.2T patent/ES2561946T3/es active Active
- 2007-11-02 US US12/513,355 patent/US8653051B2/en active Active
- 2007-11-02 HR HRP20160108T patent/HRP20160108T1/hr unknown
- 2007-11-02 CN CN201310556256.6A patent/CN103599536A/zh active Pending
- 2007-11-02 SI SI200731745T patent/SI2086544T1/sl unknown
- 2007-11-02 BR BRPI0718396-8A2A patent/BRPI0718396A2/pt not_active IP Right Cessation
- 2007-11-02 ZA ZA200903835A patent/ZA200903835B/xx unknown
- 2007-11-02 US US12/513,358 patent/US8575139B2/en not_active Expired - Fee Related
- 2007-11-02 NZ NZ577390A patent/NZ577390A/xx not_active IP Right Cessation
- 2007-11-02 CN CN2007800474487A patent/CN101563086B/zh not_active Expired - Fee Related
- 2007-11-02 NZ NZ577393A patent/NZ577393A/xx not_active IP Right Cessation
- 2007-11-02 CA CA2668320A patent/CA2668320C/en not_active Expired - Fee Related
- 2007-11-02 HU HUE07834663A patent/HUE026752T2/en unknown
- 2007-11-02 MX MX2009004696A patent/MX2009004696A/es not_active Application Discontinuation
- 2007-11-02 JP JP2009535226A patent/JP2010509211A/ja not_active Withdrawn
- 2007-11-02 CN CN2013102891472A patent/CN103381270A/zh active Pending
- 2007-11-02 KR KR1020097011486A patent/KR20090111803A/ko not_active Ceased
- 2007-11-02 EP EP15167346.4A patent/EP2937086A1/en not_active Withdrawn
- 2007-11-02 WO PCT/NL2007/050535 patent/WO2008054215A2/en not_active Ceased
- 2007-11-02 PL PL07834663T patent/PL2086544T3/pl unknown
- 2007-11-02 ZA ZA200903837A patent/ZA200903837B/xx unknown
- 2007-11-02 JP JP2009535228A patent/JP2010509213A/ja active Pending
- 2007-11-02 AU AU2007314736A patent/AU2007314736B2/en not_active Ceased
- 2007-11-02 ZA ZA200903836A patent/ZA200903836B/xx unknown
- 2007-11-02 RU RU2009120990/15A patent/RU2463054C2/ru not_active IP Right Cessation
- 2007-11-02 EP EP07834664A patent/EP2086545A2/en not_active Withdrawn
- 2007-11-02 KR KR1020097011485A patent/KR20090115113A/ko not_active Ceased
- 2007-11-02 AU AU2007314734A patent/AU2007314734B2/en not_active Ceased
- 2007-11-02 DK DK07834663.2T patent/DK2086544T3/en active
- 2007-11-02 AU AU2007314735A patent/AU2007314735B2/en not_active Ceased
- 2007-11-02 RU RU2009120992/15A patent/RU2491073C2/ru not_active IP Right Cessation
- 2007-11-02 CA CA2668317A patent/CA2668317C/en not_active Expired - Fee Related
- 2007-11-02 RU RU2009120988/15A patent/RU2464027C2/ru not_active IP Right Cessation
- 2007-11-02 JP JP2009535227A patent/JP2010509212A/ja active Pending
- 2007-11-02 KR KR20157004613A patent/KR20150038251A/ko not_active Ceased
- 2007-11-02 UA UAA201214342A patent/UA115647C2/uk unknown
- 2007-11-02 MX MX2009004693A patent/MX2009004693A/es active IP Right Grant
- 2007-11-02 KR KR1020157022168A patent/KR20150099620A/ko not_active Ceased
- 2007-11-02 PT PT78346632T patent/PT2086544E/pt unknown
- 2007-11-02 WO PCT/NL2007/050534 patent/WO2008054214A2/en not_active Ceased
- 2007-11-02 WO PCT/NL2007/050533 patent/WO2008054213A2/en not_active Ceased
- 2007-11-02 EP EP07834663.2A patent/EP2086544B1/en active Active
- 2007-11-02 US US12/513,357 patent/US8648060B2/en active Active
- 2007-11-02 CN CNA2007800462422A patent/CN101557812A/zh active Pending
- 2007-11-02 BR BRPI0717856-5A2A patent/BRPI0717856A2/pt active Search and Examination
- 2007-11-02 KR KR1020097011483A patent/KR101578224B1/ko not_active Expired - Fee Related
-
2009
- 2009-04-30 IL IL198459A patent/IL198459A/en active IP Right Grant
- 2009-04-30 IL IL198461A patent/IL198461A/en active IP Right Grant
- 2009-04-30 IL IL198460A patent/IL198460A/en active IP Right Grant
- 2009-06-03 NO NO20092145A patent/NO20092145L/no not_active Application Discontinuation
- 2009-06-03 NO NO20092143A patent/NO343597B1/no not_active IP Right Cessation
- 2009-06-03 NO NO20092146A patent/NO20092146L/no not_active Application Discontinuation
-
2012
- 2012-06-20 RU RU2012125827A patent/RU2646447C2/ru not_active IP Right Cessation
- 2012-07-10 US US13/545,916 patent/US8669242B2/en active Active
-
2013
- 2013-09-06 JP JP2013185156A patent/JP5748238B2/ja not_active Expired - Fee Related
- 2013-10-08 US US14/049,005 patent/US9211334B2/en not_active Expired - Fee Related
- 2013-10-16 JP JP2013215284A patent/JP2014055142A/ja active Pending
-
2014
- 2014-01-03 US US14/147,415 patent/US20140121190A1/en not_active Abandoned
- 2014-01-03 US US14/147,393 patent/US20140121189A1/en not_active Abandoned
- 2014-01-08 JP JP2014001289A patent/JP2014111608A/ja active Pending
- 2014-06-20 PH PH12014501440A patent/PH12014501440A1/en unknown
- 2014-08-12 PH PH12014501821A patent/PH12014501821B1/en unknown
-
2015
- 2015-03-16 IL IL237786A patent/IL237786A0/en unknown
- 2015-05-07 JP JP2015094573A patent/JP6357131B2/ja not_active Expired - Fee Related
- 2015-12-04 US US14/960,204 patent/US9597335B2/en not_active Expired - Fee Related
-
2016
- 2016-02-12 CY CY20161100116T patent/CY1117191T1/el unknown
- 2016-10-27 IL IL248563A patent/IL248563B/en active IP Right Grant
-
2017
- 2017-02-21 US US15/438,547 patent/US10314848B2/en not_active Expired - Fee Related
- 2017-05-10 JP JP2017093563A patent/JP2017132809A/ja active Pending
-
2019
- 2019-05-14 US US16/412,276 patent/US20190262359A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009120990A (ru) | Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| CY1114448T1 (el) | Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας | |
| HN2004000490A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
| AR077199A1 (es) | Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia | |
| MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
| EA200601654A1 (ru) | Ингибиторы интегразы вич | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| WO2008116890A3 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| GT200600307A (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina | |
| CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
| NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
| PA8586301A1 (es) | Formulaciones de liberacion prolongada en forma de suspension | |
| CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
| EP1781277A4 (en) | COMBINATION PREPARATION | |
| MD4093B1 (ru) | Применение фармацевтической композиции для местного применения содержащей амброксол | |
| DE602004019528D1 (de) | Usammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle | |
| UA102111C2 (ru) | Фармацевтическая композиция в виде разовой пероральной дозы, которая содержит леводопу, карбидопу и энтакапон или их соли | |
| AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica | |
| PL2020999T3 (pl) | Kompozycje zawierające alfa-ketoglutaran i ich zastosowanie do modulowania wydajności mięśniowej | |
| CL2008002223A1 (es) | Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria. | |
| PA8789101A1 (es) | Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20150505 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201103 |